Viracta Therapeutics, Inc.
(NASDAQ : SNSS)

( )
SNSS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 8.42%419.050.0%$8674.93m
BNTXBioNTech SE 17.80%414.440.0%$1709.63m
NVAXNovavax, Inc. 18.69%223.8179.8%$898.59m
SNSSSunesis Pharmaceuticals, Inc. -0.92%10.720.7%$749.37m
AMGNAmgen, Inc. -6.46%228.311.3%$524.03m
BIIBBiogen, Inc. 0.03%338.101.7%$451.97m
VRTXVertex Pharmaceuticals, Inc. -0.23%199.591.9%$424.11m
GILDGilead Sciences, Inc. -0.85%69.241.0%$409.81m
REGNRegeneron Pharmaceuticals, Inc. -0.95%580.952.7%$330.19m
ILMNIllumina, Inc. 1.24%504.603.5%$271.58m
NTLAIntellia Therapeutics, Inc. 5.87%146.942.3%$204.93m
SGENSeagen Inc. 3.17%163.215.8%$137.56m
CRSPCRISPR Therapeutics AG 2.63%124.610.6%$137.02m
TBIOTranslate Bio, Inc. 0.48%37.853.3%$134.82m
EXASEXACT Sciences Corp. 1.56%105.8318.1%$131.45m

Company Profile

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.